Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1272 - Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Application Number1272
Application NameCodependent with PBAC- Intravesical Injection of Botulinum Toxin(Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder
Description of Medical ServiceTransurethral injection of Botox into the inner bladder wall, guided by cystoscopy for the treatment of urinary incontinence.
Description of Medical ConditionIdiopathic overactive bladder with urinary incontinence

Overactive bladder is caused by a dysfunction in the coordinated mechanisms that provide controlled storage and voiding of urine. This can lead to sudden urges to urinate, which may be difficult to suppress, leading to the involuntary loss of urine (incontinence). Bladder overactivity is also associated with increased pressure within the bladder, which can lead to upper urinary tract complications and renal damage. For idiopathic overactive bladder, the cause of bladder dysfunction is unknown.
Consultation ProtocolDate of release for comment 3 October 2012
PDF version Consultation Protocol (PDF 207 KB)
Word version Consultation Protocol (Word 339 KB)
Date closed for comments 8 November 2012
Final Protocol13-14 December 2012
PDF version Final Protocol (PDF 162 KB)
Word version Final Protocol (Word 341 KB)
Reports-
MSAC OutcomesPDF Version Public Summary Document (PDF 196 KB)
Word Version Public Summary Document (Word 83 KB)

Meetings for this Application

Meeting Type:Date:
PASC16-17 August 2012
13-14 December 2012
ESC -
MSAC 28 November 2013

Page currency, Latest update: 28 April, 2015